Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|October 2, 2002
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT studyLaura S Fernandes, James E Tcheng, J Conor O'Shea, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Direct stenting with the TAXUS Liberté drug-eluting stent: results from the Taxus Atlas Direct Stent StudyJohn A Ormiston, Ehtisham Mahmud, Mark A Turco, et al.
JACC. Cardiovascular Interventions|May 26, 2009
TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS programEhtisham Mahmud, John A Ormiston, Mark A Turco, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 7, 2010
Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stentsNeil J Weissman, Mark A Turco, John A Ormiston, et al.
Journal of the American College of Cardiology|July 4, 2006
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trialDuane S Pinto, Gregg W Stone, Stephen G Ellis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 19, 2011
A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trialLouis A Cannon, Dean J Kereiakes, Tift Mann, et al.
Journal of the American College of Cardiology|April 24, 2007
Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trialMark A Turco, John A Ormiston, Jeffrey J Popma, et al.
Pageof 5